» Articles » PMID: 10801128

TACI and BCMA Are Receptors for a TNF Homologue Implicated in B-cell Autoimmune Disease

Overview
Journal Nature
Specialty Science
Date 2000 May 9
PMID 10801128
Citations 347
Authors
Affiliations
Soon will be listed here.
Abstract

B cells are important in the development of autoimmune disorders by mechanisms involving dysregulated polyclonal B-cell activation, production of pathogenic antibodies, and co-stimulation of autoreactive T cells. zTNF4 (BLyS, BAFF, TALL-1, THANK) is a member of the tumour necrosis factor (TNF) ligand family that is a potent co-activator of B cells in vitro and in vivo. Here we identify two receptors for zTNF4 and demonstrate a relationship between zTNF4 and autoimmune disease. Transgenic animals overexpressing zTNF4 in lymphoid cells develop symptoms characteristic of systemic lupus erythaematosus (SLE) and expand a rare population of splenic B-Ia lymphocytes. In addition, circulating zTNF4 is more abundant in NZBWF1 and MRL-lpr/lpr mice during the onset and progression of SLE. We have identified two TNF receptor family members, TACI and BCMA, that bind zTNF4. Treatment of NZBWF1 mice with soluble TACI-Ig fusion protein inhibits the development of proteinuria and prolongs survival of the animals. These findings demonstrate the involvement of zTNF4 and its receptors in the development of SLE and identify TACI-Ig as a promising treatment of autoimmune disease in humans.

Citing Articles

Advances in B Cell Targeting for Treating Muscle-Specific Tyrosine Kinase-Associated Myasthenia Gravis.

Hu G, Zhao X, Wang Y, Zhu X, Sun Z, Yu X Immunotargets Ther. 2024; 13:707-720.

PMID: 39678139 PMC: 11646387. DOI: 10.2147/ITT.S492062.


The Antibody Drug Conjugate, Belantamab-Mafodotin, in the Treatment of Multiple Myeloma: A Comprehensive Review.

Almodovar Diaz A, Alouch S, Chawla Y, Gonsalves W Blood Lymphat Cancer. 2024; 14:71-87.

PMID: 39664714 PMC: 11631777. DOI: 10.2147/BLCTT.S490021.


Lymphocytes Change Their Phenotype and Function in Systemic Lupus Erythematosus and Lupus Nephritis.

Moysidou E, Christodoulou M, Lioulios G, Stai S, Karamitsos T, Dimitroulas T Int J Mol Sci. 2024; 25(20).

PMID: 39456692 PMC: 11508046. DOI: 10.3390/ijms252010905.


Current status of BAFF targeting immunotherapy in B-cell neoplasm.

Tagami N, Yuda J, Goto Y Int J Clin Oncol. 2024; 29(11):1676-1683.

PMID: 39222149 PMC: 11511695. DOI: 10.1007/s10147-024-02611-2.


T cell Dissimilarities in B Cell Activating Factor-Deficient Versus B Cell Activating Factor Receptor 3-Deficient Systemic Lupus Erythematosus-Prone NZM 2328 Mice as Contributors to Their Divergent Clinical Outcomes.

Stohl W, Wu Y, Stohl M ACR Open Rheumatol. 2024; 6(11):756-768.

PMID: 39143363 PMC: 11557988. DOI: 10.1002/acr2.11712.